Insight

Luis E. Raez: Always use the best therapy first in EGFR NSCLC

Luis E. Raez/X

May 8, 2025, 22:22

Luis E. Raez: Always use the best therapy first in EGFR NSCLC

Luis E. Raez, Medical Director of Memorial Cancer Institute and Co-Director of MCI/FAU Florida Cancer Center of Excellence, shared a post by Stephen V Liu, Associate Professor of Medicine at Georgetown University, adding:

“This is important data because its real world and give as a reason to always use the best therapy first, in the EGFR case is combination therapy either MARIPOSA or FLAURA2, no more single therapy unless there is a reason.”

Quoting Stephen V Liu‘s post:

“Real world outcomes for EGFR NSCLC with 1L osimertinib JTO & JTO CRR from ConcertAI, Flatiron Clinical-Genomics, and COTA databases 2018-22. Overall, median OS 28.6m and 5y OS 18%. Stark reminder that attrition is real: 33% received no 2L therapy.”

Title: Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States

Journal of Thoracic Oncology

Authors: Joshua K. Sabaria, Helena A. Yub, Parthiv J. Mahadeviac, Yanfang Liud, Levon Demirdjiane, Yen Hua Chend, Xiayi Wangf, Antonio Passaro

Read the Full Article.

Luis E. Raez

Antonio Passaro cancer Helena A. Yub Joshua K. Sabaria Levon Demirdjiane Luis E. Raez OncoDaily Oncology Parthiv J. Mahadeviac Stephen V Liu Xiayi Wangf Yanfang Liud Yen Hua Chend

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect

Linda Evangelista and Breast Cancer: How She Went Against, How She Survived, and More

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology